Brief: Journey Medical Corporation Announces U.S. FDA Acceptance Of New Drug Application For DFD-29 For The Treatment Of Rosacea
18/03/2024 13:13
March 18 (Reuters) - Journey Medical Corp DERM.O :
* JOURNEY MEDICAL CORPORATION ANNOUNCES U.S. FDA ACCEPTANCE
OF NEW
DRUG APPLICATION FOR DFD-29 FOR THE TREATMENT OF ROSACEA
* JOURNEY MEDICAL CORP: FDA HAS SET A PRESCRIPTION DRUG USER
FEE
ACT ("PDUFA") GOAL DATE OF NOVEMBER 4, 2024.
* JOURNEY MEDICAL CORP - FDA HAS SET A PRESCRIPTION DRUG
USER FEE
ACT ("PDUFA") GOAL DATE OF NOVEMBER 4, 2024
Source text for Eikon: ID:nGNX3bB8Gv
Further company coverage: DERM.O
Recent news on Fortress Biotech
See all newsFortress Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Fortress Biotech And Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
Fortress Biotech Q1 net income jumps on PRV sale
Brief: Journey Medical Corporation Secures Contract With Third Major Gpo For Emrosi